In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcus Biosciences, Inc.

https://www.arcusbio.com/

Latest From Arcus Biosciences, Inc.

Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.

Companies Research & Development

2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy

Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.

Sales & Earnings ImmunoOncology

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

ImmunoOncology Companies

Pfizer, CStone Score China's Seventh Immuno-Oncology Approval

Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.

China Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register